07 November 2018
EMA/CHMP/752743/2018
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for medicinal products for human use (CHMP)

ORGAM[1] minutes for the meeting on 08 October 2018

Chair: Harald Enzmann

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review.

Of note, the minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

[1] The CHMP ORGAM is a meeting to discuss CHMP organisational matters. It is a virtual meeting, which usually takes place on Monday before the CHMP Plenary meeting. CHMP members, working party chairs and national experts together with EMA staff are participating in this forum. Depending on the nature of the issue and availability of documents and experts some ORGAM topics can be discussed at the CHMP Plenary. Please note that the ORGAM meeting is not taking place every month.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Agenda and Minutes

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda

CHMP ORGAM agenda for 08 October 2018 meeting was adopted

1.3. Adoption of the minutes

CHMP ORGAM Minutes of October 2018 meeting were adopted at the October 2018 CHMP plenary.

2. Working Parties, Committees, SAGs and Drafting Groups

2.1. General

2.1.1. Safety Working Party (SWP)

Chair: Jan Willem Van der Laan

Draft agenda for SWP meeting to be held face-to-face on 9-10 October 2018 (EMA/CHMP/SWP/621583/2018)

Action: For information

The CHMP noted the draft agenda.

Final minutes for SWP meeting held by teleconference on 25 June 2018 (EMA/CHMP/SWP/431212/2018)

Action: For information

The CHMP noted the final minutes.

Final minutes for SWP meeting held by teleconference on 21 August 2018 (EMA/CHMP/SWP/567686/2018)

Action: For information

The CHMP noted the final minutes.

2.1.2. Quality Working Party (QWP)

Chair: Keith Pugh/Blanka Hirschlerova

Guideline of quality and equivalence of topical products (EMA/678311/2018)

Presented by Sean Jones

Action: For adoption for public consultation

The guideline was presented by Sean Jones. The CHMP noted the guideline and invited to send any comments (since the final version was not tabled on time). It was agreed to come back to the guideline during October Plenary in case of very little comments and no extensive discussion is expected. If more time is needed, the guideline will be discussed further at the November ORGAM (5th November 2018). The track changes and final version of document was asked to be tabled for October Plenary.

Q&As on Quality data requirements to demonstrate suitability of multidose containers for preservative free eye drops (EMA/CHMP/QWP/677572/2018)

Presented by Blanka Hirschlerova

Action: For adoption

The document was presented by Blanka Hirschlerova. In case of no comments, the document will be considered as adopted at the October Plenary.

Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (EMA/685812/2018)

Presented by Blanka Hirschlerova

Action: For adoption

The QWP response was presented by Blanka Hirschlerova. Some minor editorial changes were proposed in the response. The CHMP adopted the QWP response.

QWP responses to CMDh questions on latex in synthetic rubber stoppers (EMA/CHMP/CVMP/QWP/660995/2018)

Presented by Blanka Hirschlerova

Action: For adoption

The document was presented by Blanka Hirschlerova. As no safety concentration for allergic reaction can be defined, setting maximum values for acceptable concentration and the development of analytical methods is not considered useful. MAH/applicants are expected to assess possible risks of natural latex residues. SmPC changes will depend on the risk assessment, if the risk is considered negligible, no warnings should be included. It was agreed to delete the sentence making reference to the widespread use of the rubber stoppers as there should not be a different quality approach based on how widespread the use of a product is. The CHMP adopted the QWP responses to CMDh questions.

Guideline on Active Substance Master File Procedure – corrections to the GL

Presented by Blanka Hirschlerova

Action: For adoption

The guideline was presented by Blanka Hirschlerova. The new version of the guideline introduces administrative changes to its annexes, namely annexes 2, 3 and 4 – the same requirements apply. Mainly section 6 has been amended to clarify the responsibilities of the Marketing Authorisation Holder in provision of information on S.4 Control of active substance and S.5 Reference Standard. A reference to ASMF worksharing procedure has also been included in Section 5. In case of no comments, the document will be considered as adopted at the October Plenary.

2.1.3. Scientific Advice Working Party (SAWP)

Chair: Robert Hemmings

Call for nomination of new SAWP delegates

Action: For agreement

The following expertise areas will need to be filled:

- Statistics, Novel methodologies
- Cardiology, Diabetes
- Central Nervous System, Geriatrics
- Pharmacokinetics, Modelling & Simulation

The CHMP noted the call for nomination of new SAWP delegates. Nominations should be submitted in writing. Appointment of new SAWP members will take place at the CHMP Plenary November 2018 meeting. New members are expected to be present in SAWP meetings 3 days per month and write 2-3 reports in a month. It was noted that 2 nominations (member and alternate) can be proposed per NCA.

2.1.4. European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP)

Co-chair: Kaisa Immonen

No items

2.1.5. European Medicines Agency Human Scientific Committees' Working Party with Healthcare Professionals' Organisations (HCPWP)

Co-chair: Gonzalo Calvo

No items

2.1.6. Geriatric Expert Group (GEG)

Chair: Katarina Vučić

No items

2.1.7. Committees

Area of expertise for CHMP Co-opted member

CHMP should start discussion on area of expertise in light of the expiry of the mandate of co-opted member Koenraad Norga on 24 January 2019

Action: For discussion

The CHMP noted that discussion on area of expertise should be started. Further discussions are expected at the October Plenary and members were invited to propose areas of expertise needed.

Paediatric Committee (PDCO): Final reflection paper on the use of extrapolation in the development of medicines for paediatrics

CHMP: Rob Hemmings,

Action: For discussion

The reflection paper was presented by Rob Hemmings. The reflection paper aims to provide guidance to applicants and assessors on the main regulatory requirements that are expected to be met for the use and the evaluation of extrapolation approaches in the development of medicines for children. The focus of the paper is on extrapolation to address one or more specific research questions, related to either of efficacy and/or safety as part of a broader paediatric development plan aimed at MA. GCG comments were taken into account. The CHMP noted the reflection paper. Further discussions and short presentation will be done at the October Plenary.

2.1.8. International Council on Harmonisation (ICH)

No items

2.1.9. Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (J 3RsWG)

Chair: Ellen-Margrethe Vestergaard, Co-Chair: Susanne Brendler-Schwaab

No items

2.1.10. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)

Chair: Nienke Rodenhuis

No items

2.1.11. Joint CVMP-CHMP antimicrobial advice ad hoc expert group (AMEG)

Chair: Gérard Moulin

No items

2.1.12. Modelling and Simulation Working Party (MSWP)

Chair: Kristin Karlsson/Flora Musuamba Tshinanu

Nomination of additional expert to MSWP

Presented by Kristin Karlsson

Action: For adoption

The CHMP nominated Catherine Byrne from the HPRA as additional expert to MSWP.

Paediatric modelling Q&A (EMA/168474/2018) – 3 questions:

- Presentation of PK Results/Predictions for dose selection in children
- Fixed or estimated values for allometric scaling exponents in paediatric PK models
- Ontogeny/organ maturation in paediatric models

Presented by Kristin Karlsson

Action: For adoption

The Questions and Answers document was presented by Kristin Karlsson. The document contains three questions related to PK assessment of modelling in the paediatric population. Some editorial amendments were proposed in the document before final release. The CHMP adopted the document.

2.2. Biologicals

2.2.1. Biosimilar Medicinal Product Working Party (BMWP)

Chair: Elena Wolff-Holz/Niklas Ekman

No items

2.2.2. Biologicals Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Final minutes from July face-to-face meeting held 16-18 July 2018 (EMA/CHMP/BWP/494863/2018)

Action: For information

The CHMP noted the final minutes.

Draft agenda for BWP face-to-face meeting to be held 8-10 October 2018 (EMA/CHMP/BWP/566496/2018)

Action: For information

The CHMP noted the draft agenda.

Questions and answers on Bovine Spongiform Encephalopathies (BSE) and vaccines (EMA/CHMP/BWP/192228/2017)

Action: For adoption

- Overview of comments received on 'Questions and Answers on Bovine Spongiform Encephalopathies (BSE) and vaccines' (EMEA/CHMP/BWP/637549/2018)

Action: For information

The Questions and answers document was presented. This is an update of the information in the Public Statement on the Evaluation of Bovine Spongiform Encephalopathies (BSE) - risk via the use of materials of bovine origin in or during the manufacture of vaccines and the Questions and Answers on Bovine Spongiform Encephalopathies (BSE) and Vaccines. The public statement and Q&A were intended to provide an assessment of the risk, due to BSE, of the use of bovine materials in vaccines when they were drafted in 2001. In case of no comments, the document will be considered as adopted at the October Plenary. The CHMP noted the overview of comments received.

Questions and answers on the Haemagglutination Inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations (EMA/CHMP/BWP/426390/2017)

Action: For adoption

- Overview of comments received on "Questions and answers on the Haemagglutination Inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations" (EMEA/CHMP/BWP/652969/2018)

Action: For information

The Questions and answers document was presented. Based on the experience from recent evaluations of Annual Update applications for influenza vaccines (inactivated), both regulators and industry have requested further guidance on the regulatory requirements of HI testing as applied for the qualification of influenza seed virus preparations. Whilst some of the principles outlined below may be applicable to live attenuated influenza vaccines (LAIV), there are additional considerations for the qualification of seed virus preparations using HI testing for LAIVs and hence these are outside the scope of this Q&A document. In case of no comments, the document will be considered as adopted at the October Plenary. The CHMP noted the overview of comments received.

Guideline on quality aspects included in the product information for vaccines for human use (EMA/CHMP/658682/2018)

Action: For adoption

- Overview of comments received on 'Guideline on quality aspects included in the product information for vaccines for human use' (EMEA/CHMP/BWP/668918/2018)

Action: For information

The Questions and answers document was presented. The aim of the revised guideline is to provide applicants and regulators with harmonised guidance on the quality aspects to be included in the summary of product characteristics (SmPC), package leaflet (PL) and labelling for vaccines for human use. This guideline should be read in conjunction with the other guidelines and documents which are referenced in this document. Applicants are advised to take this guideline into account when submitting new applications for Marketing Authorisation (MA) for vaccines, and may consider it when applying for renewal of, or variations to, existing MAs for vaccines for human use, where the product information is already approved. In case of no comments, the document will be considered as adopted at the October Plenary. The CHMP noted the overview of comments received.

Revision of the CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products (EMA/CHMP/BWP/303353/2010 Rev 1)

Action: For adoption for public consultation (Presentation by Sol Ruiz)

The document was presented by Sol Ruiz. The purpose of this revision is to account for the scientific developments since the last revision in 2011. The scientific information has been updated. However, there is no change in the regulatory recommendations regarding exclusion, potential testing of donors, the need to evaluate the prion reduction capacity of the manufacturing process, and batch recalls. The GCG comments were taken into account.

In case of no comments, the document will be considered as adopted for public consultation at the October Plenary.

2.2.3. Vaccines Working Party (VWP)

Chair: Mair Powell/Svein Rune Andersen

Final joint guideline with IDWP on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease.

Action: For adoption

The guideline was presented by Mair Powell. The guideline comes into effect in May 2019. The guideline addresses clinical development programmes for medicinal products intended for the pre-exposure prophylaxis or treatment of disease due to respiratory syncytial virus (RSV). The guidance covers the development of vaccines and monoclonal antibodies for the prevention of RSV disease and direct acting antiviral agents (DAAs) for the treatment of RSV disease. The CHMP adopted the guideline.

2.2.4. Blood Products Working Party (BPWP)

Chair: Jacqueline Kerr

Guideline on clinical investigation of recombinant and human plasma-derived factor IX products (EMA/CHMP/BPWP/144552/2009 rev. 2)

Action: For adoption

The guideline is expected to be tabled and discussed at November ORGAM.

Guideline on core SmPC for human plasma derived and recombinant coagulation factor IX products (EMA/CHMP/BPWP/1625/1999 rev. 3)

Action: For adoption

The guideline is expected to be tabled and discussed at November ORGAM.

2.2.5. Pharmacogenomics Working Party (PGWP)

Chair: Krishna Prasad/Markus Paulmichl

No items

2.3. Therapeutics

2.3.1. Cardiovascular Working Party (CVSWP)

Chair: Kristina Dunder/Alar Irs

Paediatric addendum to CHMP guidelines on the clinical investigations of medicinal products for the prevention and treatment of thromboembolic disease (EMA/CHMP/763438/2017)

Action: For adoption for public consultation

The document was presented by Kristina Dunder. The comments from GCG were taken into account. In case of no comments, the document will be considered as adopted at the October Plenary.

Concept Paper on the revision of the Guideline on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease (CPMP/EWP/714/98 rev.1) (EMA/CHMP/78339/2018)

Action: For adoption for public consultation

The Concept paper was presented by Kristina Dunder. There are several points (scope of the document to reflect the evolution in clinical definitions and guidelines, clinical classifications to describe the symptomatic severity of the disease, issues relevant for the increasing population of patients with coexisting diabetes and PADs, endpoints to establish efficacy in different settings, the concept of estimands and issues specific to ATMP development for PAD not covered in general ATMP guidance documents), which are proposed to be addressed in the update. It is anticipated that the draft Guideline may be released 18 months after adoption of the Concept Paper by the CHMP. The draft document will then be released for 6 months of external consultation and following the receipt of comments it will be finalised within approximately 12 months. In case of no comments, the document will be considered as adopted at the October Plenary.

2.3.2. Central Nervous System Working Party (CNSWP)

Chair: Karl Broich/André Elferink

No items

2.3.3. Infectious Diseases Working Party (IDWP)

Chair: Maria Jesus Fernandez Cortizo

No items

2.3.4. Oncology Working Party

Chair: Pierre Demolis/Paolo Foggi

Nomination of new additional assessor

Action: For adoption

The CHMP nominated Larissa Higgins (IE), who is replacing Cormac Owens, as additional assessor to Oncology Working Party.

2.3.5. Pharmacokinetics Working Party (PKWP)

Chair: Jan Welink/Henrike Potthast

Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally acting products in the gastrointestinal tract (CPMP/EWP/239/95 Rev. 1)

Rapporteur: Alfredo Garcia-Arieta

Action: For adoption

- Overview of comments received on 'Guideline on equivalence studies for the demonstration of therapeutic equivalence for products that are locally applied, locally acting in the gastrointestinal tract (EMA/CPMP/EWP/239/95 Rev.1)

  Action: For information

The guideline was presented by Alfredo Garcia-Arieta. The guideline defines the requirements that need to be fulfilled to waive clinical trials with clinical or pharmacodynamic endpoints in the demonstration of therapeutic equivalence for locally applied, locally acting gastrointestinal products. It also defines the in vivo bioequivalence studies and in vitro equivalence tests that are necessary. The CHMP noted the overview of comments received. In case of no comments, the document will be considered as adopted at the October Plenary.

Draft minutes for the F2F meeting on 17-18 April 2018 (EMA/247464/2018)

Action: For information

The CHMP noted the draft minutes.

2.3.6. Biostatistics Working Party (BSWP)

Chair: Anja Schiel/Jörg Zinserling

No items

2.3.7. Rheumatology/Immunology Working Party (RIWP)

Chair: Jan Mueller-Berghaus/Romaldas Mačiulaitis

Draft Agenda for the teleconference meeting on 21 September 2018 (EMA/CHMP/658682/2018)

Action: For information

The CHMP noted the draft agenda.

Draft Minutes for the teleconference meeting on 11 July 2018 (EMA/481994/2018)

Action: For information

The CHMP noted the draft minutes.

2.3.8. Scientific Advisory Groups (SAGs)

No items

2.3.9. Drafting Groups (DGs)

No items

2.3.9.1. Gastroenterology Drafting Group (GDG)

Chair: Mark Ainsworth

No items

2.3.9.2. Respiratory Drafting Group (RDG)

Chair: Karolina Törneke

Call for nomination of a new Chair

Action: For information

Nominations should be sent.

The CHMP noted the call for nomination.

2.3.9.3. Radiopharmaceutical Drafting Group (RadDG)

Chair: Anabel Cortes

No items

2.3.9.4. Excipients Drafting Group

Chair: Dominique Masset

No items

2.3.10. Additional agenda points

2.3.10.1. Innovation Task Force

ITF Briefing Meeting:

Meeting date: 10 October 2018.
Action: For discussion and agreement

The CHMP agreed to the meeting.

ITF Briefing Meeting:

Meeting date: 10 October 2018.
Action: For discussion and agreement

The CHMP agreed to the meeting.

Minutes of ITF Briefing meeting held on 28th June 2018

Action: For information

The CHMP noted the minutes.

Minutes of ITF Briefing meeting held on 2nd July 2018

Action: For information

The CHMP noted the minutes.

ITF Briefing meeting report from the meeting held on 4th September 2018

Action: For information

The CHMP noted the minutes.

2.3.10.2. Guideline Consistency Group (GCG)

Chair: Aranzazu Sancho-Lopez

No items

2.3.10.3. IPRF Nano Working Group

Chair: Harald Enzmann/Jean Louis Robert

No items

3. List of participants

CHMP Chair:

Harald Enzmann

CHMP members:

Concepcion Prieto Yerro

Daniela Melchiorri

Ewa Balkowiec Iskra

Frantisek Drafi

Greg Markey

Blanka Hirschlerova

Jayne Crowe

Johann Lodewijk Hillege

Katarina Vučić

Kristina Dunder

Outi Mäki-Ikola

Robert James Hemmings

Simona Badoi

Sinan B. Sarac

CHMP alternate members:

Dana Gabriela Marin

Martina Weise

Experts:

Aranzazu Sancho-Lopez

Kristin Karlsson

Maria Escudero Galindo

Mette Tranholm

Patricia Diaz Ramos

Sabine Mayrhofer

Sean Jones

Valerie Lescrainier

The meeting was run with support from the relevant EMA staff